Spots Global Cancer Trial Database for EPO906 Therapy in Patients With Advanced Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EPO906 Therapy in Patients With Advanced Kidney Cancer
Official Title: An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer
Study ID: NCT00035243
Conditions
Interventions
Study Description
Brief Summary: This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Medical Center, Los Angeles, California, United States
University of Maryland, Baltimore, Maryland, United States
Wayne State University Karmanos Cancer Center, Detroit, Michigan, United States
Our Lady Of Mercy Medical Center, Bronx, New York, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
University of Washington, Seattle, Washington, United States
Centre L. Berard, Lyon, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
